Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01461837
PHASE2

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Sponsor: New York Medical College

View on ClinicalTrials.gov

Summary

This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk sickle cell disease patients. Funding Source - FDA OOPD

Official title: Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)

Key Details

Gender

All

Age Range

2 Years - 20 Years

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2012-01

Completion Date

2026-12

Last Updated

2025-08-08

Healthy Volunteers

No

Interventions

DRUG

CD34 selected T-cell depleted allogeneic SCT

Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0

Locations (6)

University of California Los Angeles (UCLA)

Los Angeles, California, United States

Children's Hospital and Research Center Oakland

Oakland, California, United States

Lurie Children's Hospital

Chicago, Illinois, United States

Washington University/St. Louis Children's Hospital

St Louis, Missouri, United States

New York Medical College

Valhalla, New York, United States

Medical College of Wisconsin/Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States